Related Experiment Video
Updated: Dec 27, 2025
07:29
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
9.6K
Sesame lignans reduce LDL oxidative susceptibility by downregulating the platelet-activating factor acetylhydrolase
1Institute for Health Care Science, Suntory Wellness Limited, Kyoto, Japan. Yoshiko_Toyoda@suntory.co.jp.
European Review for Medical and Pharmacological Sciences
|March 7, 2020
Summary
Sesame lignans reduce low-density lipoprotein (LDL) oxidative susceptibility by decreasing plasma platelet-activating factor acetylhydrolase (PAF-AH) activity. This mechanism involves reducing liver inflammation caused by high-fat, cholesterol-rich diets.
Area of Science:
- Nutritional Biochemistry
- Cardiovascular Research
- Molecular Biology
Background:
- Low-density lipoprotein (LDL) oxidative susceptibility is a key risk factor for atherosclerosis.
- Previous studies indicated that sesame lignans reduce LDL oxidative susceptibility in humans.
Purpose of the Study:
- To investigate the underlying mechanisms by which sesame lignans reduce LDL oxidative susceptibility.
- To explore the role of plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and liver inflammation.
Main Methods:
- Rabbits were fed a fat/cholesterol-enriched diet for 6 weeks.
- Subsequent oral administration of sesame lignans or vehicle for 4 weeks.
- Assessed LDL oxidation lag time, plasma PAF-AH activity, and liver inflammatory markers.
Main Results:
- Sesame lignans prolonged LDL oxidation lag time.
- Plasma PAF-AH activity was significantly reduced by sesame lignans.
- Sesame lignans decreased pro-inflammatory cytokines and macrophage infiltration in the liver.
Conclusions:
- Sesame lignans reduce LDL oxidative susceptibility by downregulating plasma PAF-AH activity.
- This effect is mediated through the reduction of liver inflammation induced by high-fat, cholesterol-rich diets.
Related Concept Videos
01:26Atherosclerosis III: Management
272
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
272
01:30Atherosclerosis I: Introduction
684
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
684
01:19Antiasthma Drugs: Leukotriene Modifiers
1.6K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.6K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
970
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
970
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
01:38Inflammation
61.2K
Overview
61.2K